Home › Small Cell Lung Cancer › Tennessee › Nashville
Pag-aaral pangklinika para sa Small Cell Lung Cancer sa Nashville, TN
Isang pag-aaral para sa Small Cell Lung Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Nashville. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Nagre-recruitPhase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute (SCRI), Nashville
DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
- Research Site, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Nagre-recruitPhase 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Nagre-recruitPhase 3
- SCRI Oncology Partners /ID# 279779, Nashville
- Vanderbilt University Medical Center /ID# 280169, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon - Tennessee Oncology, Nashville
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Nagre-recruitPhase 3
- SCRI OP (Oncology Partners), Nashville
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Nagre-recruitPhase 3
- SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute ( Site 7001), Nashville
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Nagre-recruitPhase 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Nagre-recruitPhase 1
- Tennessee Oncology, PLLC, Nashville
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute - Oncology Partners, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site 136, Nashville
Pag-aaral para sa Small Cell Lung Cancer sa ibang lungsod
- Houston, TX26 pag-aaral
- Arlington, VA23 pag-aaral
- New York City, NY22 pag-aaral
- Boston, MA21 pag-aaral
- Los Angeles, CA20 pag-aaral
- Orlando, FL15 pag-aaral
- Dallas, TX13 pag-aaral
- Cleveland, OH13 pag-aaral
- Chicago, IL13 pag-aaral
- St. Louis, MO13 pag-aaral
- Detroit, MI12 pag-aaral
- Washington, DC12 pag-aaral
Iba pang pag-aaral sa Nashville
- Non-Small Cell Lung Cancer97 pag-aaral
- Kanser sa Suso81 pag-aaral
- Metastatic Cancer70 pag-aaral
- Colorectal Cancer69 pag-aaral
- Kanser (lahat ng uri)65 pag-aaral
- Kanser sa Ovary49 pag-aaral
- Kanser sa Prostate43 pag-aaral
- Kanser sa Baga40 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg39 pag-aaral
- Kanser sa Pancreas39 pag-aaral
- Kanser ng Endometrium38 pag-aaral
- Melanoma33 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.